全球體內CRO市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計體內 CRO 市場將從 2025 年的 54 億美元成長到 2034 年的 117.1 億美元，2026 年至 2034 年的複合年成長率為 8.97%。

隨著製藥和生物技術公司擴大將臨床前研究活動外包，全球體內CRO市場正經歷強勁成長。體內CRO進行動物實驗，以評估新藥在臨床試驗前的安全性和有效性。外包這些研究使公司能夠利用專業知識、先進的實驗室設施和法規遵循支援。

隨著藥物研發計畫的增加和生物療法的日益複雜，對體內研究服務的需求也日益成長。合約研究組織（CRO）提供廣泛的服務，包括毒性測試、藥物動力學研究和疾病模型建構。製藥公司依靠這些服務來縮短研發週期，同時維持高標準的研究品質。此外，成像技術和生物標記分析的進步也提高了體內研究的品質。

隨著全球藥物研發管線的不斷擴展，市場預計將持續成長。對生物技術研究和個人化醫療投入的增加將為合約研究組織（CRO）服務提供者創造新的機會。隨著藥物研發日益複雜，監管要求也日益嚴格，專業體內研究機構的角色將變得更加重要。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球體內CRO市場：依分子類型分類

• 市場分析、洞察與預測
• 低分子化合物
• 大分子

第5章：全球體內CRO市場：依治療領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 心臟病學
• 糖尿病
• 自體免疫疾病/發炎性疾病
• 感染疾病
• 中樞神經系統疾病
• 其他

第6章：全球體內CRO市場：依服務類型分類

• 市場分析、洞察與預測
• 臨床前試驗
• 臨床研究服務
• 檢查服務
• 諮詢服務

第7章：全球體內CRO市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • IQVIA Inc
  • Crown Bioscience Inc
  • Taconic Biosciences Inc
  • PsychoGenics Inc
  • Evotec SE
  • Janvier Labs
  • Biocytogen Co. Ltd
  • GemPharmatech Co. Ltd
  • Charles River Laboratories International
  • ICON Plc
  • Labcorp Drug Development
  • Parexel International Corporation
  • SMO Clinical Research（I）Pvt Ltd
  • WuXi AppTec Co. Ltd
  • Syneos Health

The In Vivo CRO Market size is expected to reach USD 11.71 Billion in 2034 from USD 5.40 Billion (2025) growing at a CAGR of 8.97% during 2026-2034.

The global in vivo CRO market is experiencing strong growth as pharmaceutical and biotechnology companies increasingly outsource preclinical research activities. In vivo contract research organizations conduct animal-based studies to evaluate the safety and efficacy of new drugs before clinical trials. Outsourcing these studies allows companies to access specialized expertise, advanced laboratory facilities, and regulatory compliance support.

The increasing number of drug discovery programs and the growing complexity of biological therapies are driving demand for in vivo research services. CROs provide a wide range of services including toxicology testing, pharmacokinetic studies, and disease model development. Pharmaceutical companies rely on these services to accelerate drug development timelines while maintaining high research standards. Additionally, technological advancements in imaging and biomarker analysis are improving the quality of in vivo research.

Looking forward, the market is expected to expand as the global pharmaceutical pipeline continues to grow. Increasing investment in biotechnology research and personalized medicine will create new opportunities for CRO service providers. As drug development becomes more complex and regulatory requirements become stricter, the role of specialized in vivo research organizations will become even more important.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type of Molecule

• Small Molecules
• Large Molecules

By Therapeutic Area

• Oncology
• Cardiology
• Diabetes
• Autoimmune/Inflammation Conditions
• Infectious Diseases
• CNS Conditions
• Others

By Service Type

• Preclinical Testing
• Clinical Research Services
• Laboratory Services
• Consulting Services

COMPANIES PROFILED

• IQVIA Inc, Crown Bioscience Inc, Taconic Biosciences Inc, PsychoGenics Inc, Evotec SE, Janvier Labs, Biocytogen Co Ltd, GemPharmatech Co Ltd, Charles River Laboratories International, ICON plc, Labcorp Drug Development, Parexel International Corporation, SMO Clinical Research I Pvt Ltd, WuXi AppTec Co Ltd, Syneos Health
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IN VIVO CRO MARKET: BY TYPE OF MOLECULE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Molecule
• 4.2. Small Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Large Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IN VIVO CRO MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Autoimmune/Inflammation Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. CNS Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IN VIVO CRO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Service Type
• 6.2. Preclinical Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinical Research Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Laboratory Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Consulting Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IN VIVO CRO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type Of Molecule
  • 7.2.2 By Therapeutic Area
  • 7.2.3 By Service Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type Of Molecule
  • 7.3.2 By Therapeutic Area
  • 7.3.3 By Service Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type Of Molecule
  • 7.4.2 By Therapeutic Area
  • 7.4.3 By Service Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type Of Molecule
  • 7.5.2 By Therapeutic Area
  • 7.5.3 By Service Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type Of Molecule
  • 7.6.2 By Therapeutic Area
  • 7.6.3 By Service Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL IN VIVO CRO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 IQVIA Inc
  • 9.2.2 Crown Bioscience Inc
  • 9.2.3 Taconic Biosciences Inc
  • 9.2.4 PsychoGenics Inc
  • 9.2.5 Evotec SE
  • 9.2.6 Janvier Labs
  • 9.2.7 Biocytogen Co. Ltd
  • 9.2.8 GemPharmatech Co. Ltd
  • 9.2.9 Charles River Laboratories International
  • 9.2.10 ICON Plc
  • 9.2.11 Labcorp Drug Development
  • 9.2.12 Parexel International Corporation
  • 9.2.13 SMO Clinical Research (I) Pvt Ltd
  • 9.2.14 WuXi AppTec Co. Ltd
  • 9.2.15 Syneos Health